EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
Philip CornfordRoderick C N van den BerghErik BriersThomas Van den BroeckOliver BrunckhorstJulie DarraughDaniel EberliGert De MeerleerMaria De SantisAndrea FarolfiGiorgio GandagliaSilke GillessenNikolaos GrivasAnn M HenryMichael LardasGeert J L H van LeendersMatthew LiewEstefania Linares EspinosJan OldenburgInge M van OortDaniela E Oprea-LagerGuillaume PloussardMatthew J RobertsOlivier RouvièreIvo G SchootsNatasha SchoutenEmma J SmithJohan StranneThomas WiegelPeter-Paul M WillemseDerya TilkiPublished in: European urology (2024)
This article is the summary of the guidelines for "curable" prostate cancer. Prostate cancer is "found" through a multistep risk-based screening process. The objective is to find as many men as possible with a curable cancer. Prostate cancer is curable if it resides in the prostate; it is then classified into low-, intermediary-, and high-risk localised and locally advanced prostate cancer. These risk classes are the basis of the treatments. Low-risk prostate cancer is treated with "active surveillance", a treatment with excellent prognosis. For low-intermediary-risk active surveillance should also be discussed as an option. In other cases, active treatments, surgery, or radiation treatment should be discussed along with the potential side effects to allow shared decision-making.